VEGFA and vitreous hemorrhage: However, the emergence of anti-vascular endothelial growth factor (anti-VEGF) agents (ranibizumab, bevacizumab, and aflibercept) has changed the landscape of vitreous hemorrhage in PDR treatment [5]. Anti-VEGF injections work by blocking the molecule responsible for stimulating the growth of these abnormal vessels, thereby helping reduce leakage and bleeding.